53.36 USD
▼-1.07-1.97%
盘后 60.56 0.00%
2026-09-15
市值
$3.60B
市盈率
—
EPS
-1.67
股息率
—
52 周区间
14.79 – 62.32
成交量
866.96K
Beta
0.24
目标价
73.90
52W 低 14.7952W 高 62.32
价格走势
公司简介
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and othe...